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Abstract
Introduction: Diverse bone pathologies are observed in patients with psoriatic arthritis (PsA). Uncoupling of bone
remodeling with disordered osteoclastogenesis has been implicated in the pathogenesis of PsA. The aim of this
study was to examine the role of soluble mediators of bone remodeling within the circulation of patients with PsA.
Methods: Patients with PsA (n = 38), with psoriasis (n = 10), and healthy controls (n = 12) were studied. Serum
was obtained for testing of Dikkopf-1 (Dkk-1), macrophage-colony stimulating factor (M-CSF), osteoprotegerin
(OPG), and receptor activator of nuclear factor-B ligand (RANKL) with ELISA. Patients with PsA also had bone
densitometry, plain radiographs of the hands and feet, and assessment of peripheral blood osteoclast precursors.
Radiographs were scored for erosion, joint-space narrowing, osteolysis, and new bone formation.
Results: Compared with those with psoriasis and healthy controls, patients with PsA had higher circulating
concentrations of Dkk-1 and M-CSF. In patients with PsA, M-CSF and RANKL, but not Dkk-1, concentrations
positively correlated with radiographic erosion, joint-space narrowing, and osteolysis scores. Mediators of bone
remodeling did not correlate with the number of joints with new bone formation or with total hip-bone mineral
density. Peripheral blood CD14
+/CD11b
+ cells, and the number of osteoclast-like cells and resorptive pits after
culture with RANKL and M-CSF also correlated with radiographic damage scores. Circulating M-CSF concentrations
correlated with the percentage of peripheral blood CD14
+/CD11b
+ cells.
Conclusions: Systemic expression of soluble factors that promote osteoclastogenesis is disordered in patients with
PsA and may contribute to periarticular bone loss in this disease.
Introduction
Psoriatic arthritis (PsA) is an inflammatory arthritis with
a number of characteristic clinical features [1]. PsA is
typically associated with psoriasis and psoriatic nail dis-
ease and has both peripheral articular manifestations
(including synovitis, dactylitis, and enthesitis) and axial
skeletal involvement. A range of bone pathologies is
observed in patients with PsA [2]. Bone loss can occur,
either locally in the form of bone erosion and osteolysis
affecting the peripheral joints, or systemically with loss
of skeletal bone mineral density (BMD) [3]. Aberrant
bone formation may also occur, including peripheral
juxtaarticular new bone formation, ankylosis, and syn-
desmophyte formation. These different bone pathologies
may be observed in the same patient [4].
Bone is a metabolically active tissue that is capable of
constantly remodeling in a highly coordinated manner
(reviewed in [5]). Two main cell types are involved in
bone remodeling: osteoclasts that resorb mineralized
bone and osteoblasts that are responsible for new bone
formation. Osteoclasts can be matured in vitro by cul-
ture of monocyte/macrophage precursors in the pre-
sence of macrophage-colony stimulating factor (M-CSF)
and receptor activator of nuclear factor-Bl i g a n d
(RANKL) [6,7]. Osteoprotegerin (OPG) is a further
mediator of bone remodeling, acting as a decoy receptor
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thus inhibiting osteoclastogenesis [7]. When cultured on
bone, osteoclasts derived in vitro excavate resorptive pits
that are similar to the structures formed when osteo-
clasts degrade bone in vivo. These cells also express pro-
teins that typify the osteoclast lineage, including
tartrate-resistant acid phosphatase (TRAP). Additional
soluble factors also influence bone remodeling; recent
work has demonstrated that Dickkopf (Dkk-1), an inhi-
bitor of Wnt signaling, inhibits osteoblast differentiation
and function and promotes osteoclastogenesis through
suppression of OPG [8-11].
RANKL-mediated osteoclastogenesis has been impli-
cated in the pathogenesis of bone resorption in PsA
[12-15]. In patients with PsA, osteoclasts are present at
sites of bone erosion, and osteoclasts cultured in vitro
from peripheral blood precursors exhibit increased
resorptive activity compared with those from healthy
controls [12]. Erosive disease is also associated with high
numbers of circulating cells expressing CD14 and
CD11b [12]. Intense RANKL expression has been
demonstrated within the lining layer in the PsA joint,
with more restricted sublining layer OPG expression,
implicating imbalance in the RANKL/OPG axis that, in
turn, may promote osteoclastogenesis [12]. However, the
factors regulating the various manifestations of bone dis-
ease in PsA remain uncertain.
The aim of this study was to examine the role of solu-
ble mediators of bone remodeling in the circulation of
patients with PsA. Here, we focused on four soluble
mediators that have been definitively implicated in bone
remodeling in models of inflammatory arthritis; Dkk-1,
M-CSF, RANKL, and OPG [11,16-19]. In particular, we
wished to determine the relations between these media-
tors and patterns of bone pathology in PsA.
Materials and methods
Patients and clinical assessments
This study was approved by the New Zealand Multire-
gion Ethics Committee, and all patients provided written
informed consent. Thirty-eight patients with PsA were
recruited from rheumatologyc l i n i c si nt h eA u c k l a n d ,
Rotorua, and Wellington regions of New Zealand. All
patients with PsA met the Classification of Psoriatic
Arthritis (CASPAR) criteria for PsA [1]. In addition, two
control groups were studied; patients with psoriasis
(confirmed by a dermatologist) but no arthritis (n = 10),
and healthy volunteers with no psoriasis or arthritis (n =
12). Psoriasis control and healthy control participants
had no previous diagnosis of arthritis and no evidence
of synovitis, enthesitis, joint deformity, or spinal limita-
tion on physical examination at the time of recruitment.
Clinical assessments, radiographs, and blood samples
were completed at a single study visit. All participants,
including healthy control and psoriasis control partici-
pants, had collection of demographic data, recording of
relevant medical history and medications, and serum
measured for soluble mediators of bone remodeling and
C-reactive protein. Severity of psoriasis was assessed in
patients with psoriasis and PsA by using the Psoriasis
Area and Severity Index (PASI) [20], and psoriatic nail
disease was assessed by using the Psoriasis Nail Severity
Score (PNSS) [21]. Patients with PsA also had further
investigations, including assessment of arthritis disease
activity by using the disease activity score (DAS)28-CRP,
bone densitometry, plain radiographs of the hands, feet,
and sacroiliac joints, and assessment of peripheral blood
osteoclast precursors.
Radiographic assessments
Plain radiographs of the hands, feet, and sacroiliac joints
were obtained at the study visit. Plain radiographs of the
hands and feet were scored for erosions and joint-space
narrowing according to the Sharp van der Heijde score
modified for use in PsA [22], by a rheumatologist (ND)
with experience in this scoring system. Patients with at
least one erosion on hand and foot radiographs were
considered erosive for the purposes of the analysis. The
number of joints with new bone formation was recorded
by using the CASPAR definition: radiographic evidence
of juxtaarticular new bone formation appearing as ill-
defined ossification near joint margins (but excluding
osteophyte formation) on plain radiographs of the hand
or foot [1]. The number of joints in the hands and feet
with pencil-in-cup deformities was also recorded to
allow a quantitative assessment of the presence and
extent of osteolysis. Sacroiliitis was scored as present or
absent by a radiologist, according to the New York cri-
teria for sacroiliitis in ankylosing spondylitis. Proximal
femur BMD was measured by using a Prodigy dual-
energy x-ray absorptiometer (DEXA) (GE-Lunar, Madi-
son, WI). All radiographic scoring and measurement
were completed by readers who were blinded to the
clinical and laboratory findings.
Testing of soluble mediators of bone remodelling
Blood was obtained at the study visit, and serum was
separated within 3 hours of collection. Serum was sepa-
rated into at least four aliquots to avoid repeated freeze-
thaw cycles and was stored at -20°C until testing. Serum
was analyzed for soluble mediators of bone remodeling
with enzyme-linked immunosorbent assay (ELISA) by
using the following kits; Dkk-1 (R&D duoset), M-CSF
(R&D quantikine), and RANKL (Biomedica), OPG (R&D
duoset), according to the manufacturers’ instructions.
To confirm consistency between assays, three control
sera were used as internal controls for each ELISA plate.
Initial optimization assays of the Dkk-1 assay confirmed
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a patient with osteolytic metastatic bone disease
(16,527 pg/ml).
Testing of peripheral blood osteoclast precursors
Peripheral blood mononuclear cells (PBMCs) were iso-
lated with Lymphoprep (Nycomed Pharma, Oslo, Nor-
way) gradient centrifugation. The cells were analyzed for
the presence of osteoclast precursors with flow cytome-
t r ya n dc u l t u r ei nR A N K La n dM - C S F ,a sp r e v i o u s l y
described [23].
Osteoclast precursors arise from the CD14
+/CD11b
+
monocyte population [24]. The percentage of CD14
+/
CD11b
+ cells was studied with flow-cytometry analysis
of peripheral blood [12,25]. PBMCs (10
6 cells/assay)
were washed in phosphate-buffered saline (PBS) in the
presence of 0.16% bovine serum albumin and 0.1%
sodium azide and incubated for 30 minutes with saturat-
ing amounts of the anti-CD14-fluorescein isothiocyanate
(FITC) (Dako, Carpinteria, CA) and anti-CD11b-phy-
coerythrin (PE) (Dako), or appropriate fluorescein-con-
jugated isotype control antibodies. All samples were
analyzed on a FACScan by using Cell Quest Software
(both from Becton Dickinson, Mountain View, CA). The
percentage of CD14
+/CD11b
+ cells in each PBMC sam-
ple was recorded.
PBMCs (10
6 cells/ml) were placed in 24-well plates
containing 1 ml aMEM with 10% fetal bovine serum
(FBS), 100 units/ml penicillin, and 100 μg/ml streptomy-
cin. Cells were incubated at 37°C in 5% CO2 for 14 days
with and without human recombinant RANKL (30 ng/
ml; Peprotech Ltd, Rehovot, Israel) and M-CSF (25 ng/
ml, R&D Inc., Minneapolis, MN). Medium was replen-
ished every 3 to 4 days. After 14 days in culture, slides
were stained for TRAP (Sigma, Poole, UK). Slides were
viewed with light microscopy, and TRAP-positive cells
with three or more nuclei were counted as osteoclasts
by a single observer who was blinded to the clinical and
radiographic characteristics of the patients. Cells were
plated and counted in triplicate, and the mean value of
the triplicates was recorded.
The ability of these cells to resorb bone was con-
firmed in parallel assays, by culturing of PBMCs in 1 ml
10% FBS-aMEM with RANKL and M-CSF for 14 days
on ivory slices in duplicate (supplied by the Auckland
Conservancy Office, Department of Conservation, Auck-
land, New Zealand). The cultured ivory slices were
scrubbed, stained with toluidine blue, and analyzed for
resorption pits with reflected-light microscopy. The
number of pits on the entire slice was counted manually
by a single observer who was blinded to the clinical and
radiographic characteristics of the patients. The mean
value of the duplicates was recorded.
Statistical analysis
A l ld a t aw e r ea n a l y z e db yu s i n gG r a p h P a dP r i s m
(GraphPad Software, San Diego, CA). Descriptive data
are presented as n (percentage) or median (range). Dif-
ferences between groups was analyzed with c
2 tests and
Mann-Whitney tests in the case of two groups, and
one-way analysis of variance (ANOVA) (Kruskal-Wallis
test) with Dunn’s multiple comparison test in the case
of more than two groups. Spearman’sc o r r e l a t i o n sw e r e
used to explore the relation between the clinical/radio-
graphic features and laboratory results. A P value of
< 0.05 was considered significant.
Results
Clinical characteristics
Of the 38 patients with PsA, 29 had at least one erosion
on plain radiography (erosive), and nine had no erosions
(nonerosive). Clinical characteristics of the patients with
PsA, of those with psoriasis, and of healthy controls are
shown in Table 1. All groups were matched by age and
ethnicity. Some differences were observed between
groups. More women were in the healthy control group.
Psoriasis control participants had higher PASI scores
and less use of methotrexate and nonsteroidal antiin-
flammatory drugs (NSAIDs), compared with the PsA
group. Both psoriasis and healthy controls had lower
C-reactive protein concentrations than did patients with
PsA. Patients with erosive and nonerosive PsA were
similar, except for higher DAS28-CRP and radiographic-
damage scores in the erosive group. No patients were
receiving TNF inhibitors or other biologic therapy.
Soluble mediators of bone remodeling in the circulation
of patients with PsA
Compared with both healthy controls and psoriasis con-
trols, patients with PsA had higher circulating concen-
trations of Dkk-1 and M-CSF (Figure 1a and 1b). No
significant difference was found between the control
groups and the PsA group in OPG or RANKL concen-
trations (Figure 1c and 1d).
Patients with both erosive and nonerosive PsA had
higher circulating concentrations of Dkk-1, compared
with psoriasis controls (Figure 1e). In contrast, only
those with erosive PsA had higher M-CSF concentra-
tions (Figure 1f). No overall difference was noted in
RANKL or OPG concentrations between the groups of
patients with erosive and nonerosive PsA (Figure 1g
and 1h).
Relation between soluble mediators of bone remodeling
and patterns of bone disease in patients with PsA
In patients with PsA, M-CSF and RANKL concentra-
tions positively correlated with radiographic-damage
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scores, and the number of joints affected by osteolysis
(Table 2). No relation was observed between Dkk-1 con-
centrations and patterns of bone disease in these
patients. Circulating mediators of bone remodeling did
not correlate with the number of joints affected by new
bone formation or total hip BMD (including after the
adjustment for BMI; data not shown). In patients with
PsA, no relation was observed between the soluble med-
iators of bone remodeling and the following clinical fac-
tors: sex, creatinine, weight, presence of sacroiliitis,
DAS-28-CRP, or prednisone, or NSAID or methotrexate
use (data not shown).
Peripheral blood osteoclast precursors, patterns of bone
disease, and soluble mediators of bone remodeling in
patients with PsA
In patients with PsA, the percentage of CD14
+/CD11b
+
cells in peripheral blood, the number of TRAP
+ multi-
nucleated cells (MNCs), and pits after culture with
RANKL and M-CSF correlated with radiographic
damage scores (Table 3). The number of joints affected
by osteolysis also correlated with the number of TRAP
+
M N C sa n dp i t sa f t e rc u l t u r e( T a b l e3 ) .T h en u m b e ro f
pits strongly correlated with the number of TRAP
+
MNCs after culture with RANKL and M-CSF (r =0 . 5 3 ;
P = 0.001), but not with the total percentage of CD14
+/CD11b+ cells (r = 0.29; P = 0.09). After adjusting for
the number of CD14
+/CD11b
+ cells, the correlation
with TRAP
+ MNCs was no longer significant, but a per-
sistent association was found with the number of pits in
culture and radiographic damage and osteolysis (Table
3). Large numbers of spontaneously arising bone-resorb-
ing osteoclast-like cells were not observed in patients
with PsA or in control participants in the absence of
RANKL and M-CSF.
Circulating M-CSF concentrations also correlated with
the percentage of peripheral blood CD14
+/CD11b
+ cells
in patients with PsA (r = 0.40; P < 0.05), with a trend to
correlation with the number of TRAP
+ MNCs (r = 0.33;
P = 0.05). No correlation was noted between the num-
bers of pits after culture with M-CSF and RANKL and
circulating M-CSF concentrations (r = 0.21; P > 0.05).
Similarly, no correlation was observed between the
other soluble mediators of bone remodeling and mea-
sures of osteoclast precursors (data not shown).
Table 1 Clinical characteristics of study participants
All PsA
n =3 8
Erosive PsA
n =2 9
Nonerosive
PsA
n =9
Psoriasis
alone
n =1 0
Healthy
control
n =1 2
Female sex, n (%) 16 (42%) 11 (38%) 5 (56%) 4 (40%) 11 (92%)
b
Age, years, median (range) 50 (26-68) 50 (26-63) 47 (33-68) 44 (19-72) 48 (21-53)
Caucasian ethnicity, n (%) 32 (84%) 25 (86%) 7 (78%) 7 (70%) 10 (83%)
Weight, kg, median (range) 78 (32-116) 80 (65-114) 74 (32-116) 82 (67.9-103) 81 (46-109)
Psoriasis disease duration, years, median (range) 20 (0.5-50) 20 (3-50) 20 (0.5-40) 18 (0.4-53) NA
Arthritis disease duration, years, median (range) 10 (0.5-45) 11 (5-33) 5 (0.5-45) NA NA
PASI, median (range) 1.6 (0-12) 1.5 (0-12) 1.6 (1-3.4) 13 (6.3-23.2)
b NA
Nail score, median (range) 7 (0-47) 9 (0-47) 6 (0-25) 6 (0-25) NA
Creatinine, μmol/L, median (range) 77 (23-249) 78 (23-249) 77 (42-89) 76 (39-100) NA
C-reactive protein, mg/L, median (range) 6.5 (1-59) 7.2 (1-59) 5.8 (1-26) 2.6 (1-7.2)
b 2.1 (1-15)
b
DAS28-CRP, median (range) 3.9 (1.4-6.6) 4.2 (2.3-6.6) 2.7 (1.4-6.0)
a NA NA
Methotrexate use, n (%) 22 (58%) 15 (52%) 7 (78%) 1 (10%)
b 0 (0)
b
Prednisone use, n (%) 7 (18%) 4 (14%) 3 (33%) 0 (0) 0 (0)
Nonsteroidal antiinflammatory drug use, n (%) 19 (50%) 16 (55%) 3 (33%) 0 (0)
b 0 (0)
b
Biologics use, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
XR erosion score, median (range) 29 (0-183) 43 (1-183) 0 (0-0)
a NA NA
XR narrowing score, median (range) 24.5 (0-160) 36 (2-160) 0 (0-10)
a NA NA
Combined XR score, median (range) 59 (0-343) 78 (3-343) 0 (0-10)
a NA NA
Number of joints with pencil-in-cup deformities on XR, median
(range)
0 (0-17) 0 (0-17) 0 (0-0) NA NA
Number of joints with new bone formation on XR, median (range) 1 (0-9) 1 (0-9) 0 (0-7) NA NA
Radiographic sacroiliitis, n (%) 15 (39%) 12 (41%) 3 (33%) NA NA
Total hip BMD T score, median (range) -0.1 (-3.5-2.0) -0.1 (-2.1-2.0) -0.2 (-3.5-0.9) NA NA
aP < 0.05, compared with erosive PsA;
bP < 0.05, compared with all PsA. BMD, bone mineral density DAS, disease activity score; PASI, Psoriasis Area and Severity
Index; XR, x-ray. NA, not assessed.
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This study has allowed analysis of the relation between
circulating factors of bone remodeling and patterns of
bone pathology in PsA. The results provide further evi-
dence for uncoupling of bone remodeling in patients
with PsA. The soluble factors analyzed in this study are
key regulators of bone turnover, and our data suggest
that systemic expression of factors promoting osteoclas-
togenesis and bone loss (Dkk-1, M-CSF, RANKL) is dis-
ordered in patients with PsA.
Bone pathology in PsA may occur at a number of dif-
ferent sites, affecting both articular sites (erosion, osteo-
lysis, and new bone formation) and the skeleton in a
generalized manner (loss of BMD). In this study,
Figure 1 Soluble mediators of bone remodeling in the circulation of patients with PsA. Box-and-whisker plots showing concentrations of
(a) Dkk-1, (b) M-CSF, (c) OPG, and (d) RANKL in healthy controls (HCs), patients with psoriasis (Ps) and patients with PsA. Box-and-whisker plots
showing concentrations of (e) Dkk-1, (f) M-CSF, (g) OPG, and (h) RANKL in patients with psoriasis (Ps) and patients with nonerosive PsA, and
patients with erosive PsA. Median values for RANKL for the healthy control, all PsA, and erosive PsA groups were 0.031 pmol/L. *P < 0.05;
**P < 0.01; ***P < 0.001; one-way ANOVA with Dunn’s multiple comparison test.
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tify patterns of peripheral joint bone loss and bone for-
mation, and the relation between these patterns of bone
pathology and soluble mediators of bone remodeling
was analyzed. Our data indicate that the extent of bone
loss at the peripheral joint is associated with elevated
circulating M-CSF and RANKL concentrations, but that
these factors are not associated with the extent of sys-
temic bone loss in PsA. Furthermore, we have not iden-
tified circulating factors that are associated with
peripheral new bone formation in this disease. Spinal
radiographs were not obtained as part of this study, and
it is possible that alterations in circulating markers of
bone-remodeling factors may be associated with other
forms of new bone formation in PsA, such as syndesmo-
phyte formation in the axial skeleton. This study
assessed sacroiliitis with plain radiography by using a
widely recognized scoring method of established bone
change. Although no relation between circulating bone-
remodeling markers and sacroiliitis was observed, it is
possible that that inflammation of the sacroiliac joints
was underestimated by using this method, compared
with a more-sensitive method such as magnetic reso-
nance imaging [26,27].
A key finding of this study is the elevated serum Dkk-
1 concentrations with patients with PsA, compared with
those in patients with psoriasis and healthy control par-
ticipants. Dkk-1 has been strongly implicated in joint
remodeling in inflammatory arthritis; blockade of this
factor inhibits osteoclastogenesis and bone erosion in
in vivo models of RA, even in the presence of persistent
joint inflammation [11]. Furthermore, blockade of Dkk-
1 promotes development of osteophytes in these models,
indicating a role in regulation of new bone formation
[11]. Elevated serum Dkk-1 concentrations have pre-
viously been reported in patients with active RA [11].
Interestingly, we have not identified a specific relation
between serum Dkk-1 concentrations and patterns of
bone pathology in PsA, in the form of either new bone
formation or bone loss. PsA is a heterogeneous disease,
and it is possible that this study was not powered to
identify differences in Dkk-1 concentrations between
disease subsets, which may overlap. However, these find-
ings are consistent with a previous study of serum
Table 2 Stromal cell-derived mediators of bone remodeling and bone pathology scores in patients with PsA
Median
(range)
XR
erosion
score
XR
narrowing
score
Combined
XR score
Number of joints with pencil-
in-cup deformities on XR
Number of joints with new
bone formation on XR
Total hip
BMD T score
Dkk-1 2,977 (1,163-
5,908) pg/ml
0.15 0.10 0.15 -0.12 0.22 -0.13
M-CSF 408 (120-
1,166) pg/ml
0.53
b 0.54
b 0.52
b 0.36
a 0.09 -0.06
OPG 1,871 (179.5-
7,367) pg/ml
-0.13 -0.03 -0.08 0.09 -0.12 -0.10
RANKL 0.031 (0-0.49)
pmol/L
0.36
a 0.35
a 0.36
a 0.41
a 0.08 -0.03
aP <0 . 0 5 ;
bP < 0.01. Spearman r values for correlations between circulating concentrations of stromal cell-derived mediators of bone remodeling and measures
of bone pathology. BMD, bone mineral density; Dkk-1, Dikkopf-1; M-CSF, macrophage-colony stimulating factor; OPG, osteoprotegerin; RANKL, receptor activator
of nuclear factor-B ligand; XR, x-ray.
Table 3 Cellular markers of bone remodeling and bone pathology scores in patients with PsA
Median
(range)
XR
erosion
score
XR
narrowing
score
Combined
XR score
Number of joints with
pencil-in-cup deformities
on XR
Number of joints with
new bone formation
on XR
Total hip
BMD T
score
Percentage CD11b
+/CD14
+
cells (% all PBMCs)
3.3 (0.04-9.0) 0.35
a 0.36
a 0.38
a 0.11 0.03 -0.20
TRAP
+ MNCs (per 10
6
PBMCs)
c
29 (0-913) 0.31 0.41
a 0.37
a 0.34
a 0.00 -0.18
TRAP
+ MNCs adjusted for
number of CD11b
+/CD14
+
cells
c
9 (0-454) 0.18 0.21 0.17 0.28 0.00 -0.10
Number of pits (per 10
6
PBMCs)
0 (0-500) 0.43
a 0.48
b 0.46
b 0.41
a 0.00 -0.33
Number of pits adjusted for
number of CD11b
+/CD14
+
cells
c
0 (0-371) 0.45
b 0.49
b 0.47
b 0.45
b 0.01 -0.30
aP <0 . 0 5 ;
bP <0 . 0 1 ;
cafter culture with RANKL and M-CSF. Spearman r values for correlations between cellular markers and measures of bone pathology. BMD,
bone mineral density; M-CSF, macrophage-colony stimulating factor; MNCs, multinucleated cells; PBMCs, peripheral blood mononuclear cells; RANKL, receptor
activator of nuclear factor-B ligand; TRAP, tartrate-resistant acid phosphatise; XR, x-ray.
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did not show an association with radiographic damage
in rheumatoid arthritis (RA) (by using the Sharp score)
or ankylosing spondylitis (by using the modified Stoke
Ankylosing Spondylitis Spine Score (mSASSS)) [28]. The
elevated serum Dkk-1 concentration in our study differs
from that in the recent study of patients with inflamma-
tory arthritis that included a small PsA group [28].
A further consideration is that serum Dkk-1 concentra-
tions may not reflect the biologic activity of this media-
tor, particularly in the context of inflammatory disease
[28]. Together, these observations indicate uncertainty
about the role and significance of circulating concentra-
tions of Dkk-1 in the development of bone disease in
inflammatory arthritis.
M-CSF promotes macrophage survival and prolifera-
tion and is a key regulator of osteoclastogenesis [29].
This cytokine is required for culture of osteoclasts in
vitro and has been strongly implicated in the pathogen-
esis of TNF-induced osteolysis in animal models [16,30].
We showed that circulating concentrations of M-CSF
are elevated in the patients with erosive PsA and
strongly correlate with severity of peripheral erosive dis-
ease. Circulating M-CSF concentrations also correlated
with the percentage of peripheral blood CD14
+/CD11b
+
cells in patients with PsA, but not with the number of
TRAP
+ MNCs or the number of resorptive pits after
2-week culture with M-CSF and RANKL. These results
suggest that circulating M-CSF might promote survival
or release of circulating osteoclast precursor cells, rather
than differentiation or activity of osteoclasts. However, it
s h o u l db en o t e dt h a tb o t hM - C S Fa n dR A N K Lw e r e
added to the osteoclast-differentiation cultures; thus, a
biologic effect of M-CSF on osteoclast development or
activity in vivo cannot be excluded entirely.
The factors tested in this study are likely to have spe-
cific effects within the local joint environment, which
may not be entirely reflected by circulating concentra-
tions. For example, it has been reported that OPG
expression is limited to endothelial cells below the syno-
vial membrane within the psoriatic joint [12]; in con-
trast, we did not identify reduced circulating OPG
concentrations in patients with PsA or a relation
between these concentrations and patterns of bone
remodeling. Our data do raise the possibility that other
circulating mediators, such as M-CSF or RANKL, may
h a v ear o l ea sb i o m a r k e r st oi d e n t i f yp a t i e n t sw i t hP s A
in whom progressive or accelerated joint damage will
develop. One of the key aspects of biomarker develop-
ment is feasibility, and measurement of soluble markers
within the circulation, rather than within synovial tissue,
is clearly a major advantage in this respect [31]. Pro-
spective studies are required to validate these factors
further as biomarkers in PsA [32].
Consistent with the work of Ritchlin et al. [12], our
study also implicates RANKL in the pathogenesis of
bone erosion in PsA, noting the modest correlation
between circulating RANKL concentrations and mea-
sures of peripheral-joint bone loss. Furthermore, we
demonstrated that the percentage of circulating CD14
+/CD11b
+ cells correlates with the extent of the erosive
disease, and that osteoclasts arising from peripheral
blood precursors have a greater capacity to resorb bone
in those with more-severe erosive disease. It is of inter-
est that circulating concentrations of both M-CSF and
RANKL are associated with bone loss at a local level
within the peripheral joints, but not with systemic BMD.
Similar conclusions can also be made regarding the
assessment of circulating osteoclast precursors. These
findings imply that other factors within the local joint
environment, perhaps alterations in osteoblast function
or expression of proinflammatory cytokines such as
TNF-a, may act in concert with these soluble mediators
of bone remodeling to promote osteoclastogenesis, and,
in turn, bone erosion.
Conclusions
This work has shown that systemic expression of soluble
mediators of bone remodeling is disordered in PsA. Fac-
tors that promote osteoclastogenesis or inhibit osteo-
blast function are elevated in the circulation of patients
with PsA and may contribute to periarticular bone loss
in this disease. Prospective studies will be of interest to
determine the role of these factors in progression of
bone resorption and the effects of treatment in patients
with PsA.
Abbreviations
ANOVA: analysis of variance; BMD: bone mineral density; CASPAR:
Classification of Psoriatic Arthritis; DAS: disease activity score; DEXA: dual-
energy x-ray absorptiometer; DKK-1: Dikkopf-1; ELISA: enzyme-linked
immunosorbent assay; M-CSF: macrophage-colony stimulating factor; MNCS:
multinucleated cells; MSASSS: modified Stoke Ankylosing Spondylitis Spine
Score; OPG: osteoprotegerin; PASI: Psoriasis Area and Severity Index; PBMCS:
peripheral blood mononuclear cells; PNSS: Psoriasis Nail Severity Score; PSA:
psoriatic arthritis; RA: rheumatoid arthritis; RANK: receptor activator of nuclear
factor-B; RANKL: receptor activator of nuclear factor-B ligand; TNF: tumor
necrosis factor; TRAP: tartrate-resistant acid phosphatase; XR: x-ray.
Acknowledgements
This study was funded by the Auckland Medical Research Foundation, the
Auckland Regional Rheumatology Research Trust, and the QE Hospital
Community Trust. Partial support for this study also was provided by an
investigator-initiated grant from Novartis.
Author details
1Department of Medicine, University of Auckland, 85 Park Rd, Auckland 1010,
New Zealand.
2Department of Rheumatology, Auckland District Health
Board, Greenlane West, Auckland 1051, New Zealand.
3Department of
Medicine, University of Otago, Wellington, Mein St, Wellington 6021, New
Zealand.
4Waikato Clinical School, University of Auckland, Pembroke Street,
Hamilton 3240, New Zealand.
5Department of Molecular Medicine and
Pathology, University of Auckland, 85 Park Rd, Auckland 1010, New Zealand.
Dalbeth et al. Arthritis Research & Therapy 2010, 12:R164
http://arthritis-research.com/content/12/4/R164
Page 7 of 9Authors’ contributions
ND contributed to study conception and design, data analysis and
interpretation, drafting of manuscript, and final approval of the manuscript.
BP, TS, KEC, and ML contributed to acquisition and analysis of data, revision
of the manuscript, and final approval of the manuscript. WJT, PJ, JC, and
FMM contributed to study conception and design, data interpretation,
revision of the manuscript, and final approval of the manuscript.
Competing interests
Partial support for this study was provided by an investigator-initiated grant
from Novartis. No other competing interests are declared.
Received: 18 June 2010 Revised: 4 August 2010
Accepted: 26 August 2010 Published: 26 August 2010
References
1. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H:
Classification criteria for psoriatic arthritis: development of new criteria
from a large international study. Arthritis Rheum 2006, 54:2665-2673.
2. Taylor WJ, Porter GG, Helliwell PS: Operational definitions and observer
reliability of the plain radiographic features of psoriatic arthritis. J
Rheumatol 2003, 30:2645-2658.
3. Frediani B, Allegri A, Falsetti P, Storri L, Bisogno S, Baldi F, Filipponi P,
Marcolongo R: Bone mineral density in patients with psoriatic arthritis. J
Rheumatol 2001, 28:138-143.
4. Ly J, Pinto C, Doyle A, Dalbeth N, McQueen FM: Axial bone proliferation
causing cervical myelopathy in the mutilans form of psoriatic arthritis
despite peripheral bone erosion. Ann Rheum Dis 2009, 68:443-444.
5. Teitelbaum SL: Osteoclasts: what do they do and how do they do it? Am
J Pathol 2007, 170:427-435.
6. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S,
Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K,
Udagawa N, Takahashi N, Suda T: Osteoclast differentiation factor is a
ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is
identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998, 95:3597-3602.
7. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R,
Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E,
Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G,
Guo J, Delaney J, Boyle WJ: Osteoprotegerin ligand is a cytokine that
regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
8. Bafico A, Liu G, Yaniv A, Gazit A, Aaronson SA: Novel mechanism of Wnt
signalling inhibition mediated by Dickkopf-1 interaction with LRP6/
Arrow. Nat Cell Biol 2001, 3:683-686.
9. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr:
The role of the Wnt-signaling antagonist DKK1 in the development of
osteolytic lesions in multiple myeloma. N Engl J Med 2003, 349:2483-2494.
10. Morvan F, Boulukos K, Clement-Lacroix P, Roman S, Suc-Royer I, Vayssiere B,
Ammann P, Martin P, Pinho S, Pognonec P, Mollat P, Niehrs C, Baron R,
Rawadi G: Deletion of a single allele of the Dkk1 gene leads to an
increase in bone formation and bone mass. J Bone Miner Res 2006,
21:934-945.
11. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A,
Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewe R,
Lacey D, Richards WG, Schett G: Dickkopf-1 is a master regulator of joint
remodeling. Nat Med 2007, 13:156-163.
12. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM: Mechanisms of
TNF-alpha- and RANKL-mediated osteoclastogenesis and bone
resorption in psoriatic arthritis. J Clin Invest 2003, 111:821-831.
13. Colucci S, Brunetti G, Cantatore FP, Oranger A, Mori G, Quarta L, Cirulli N,
Mancini L, Corrado A, Grassi FR, Grano M: Lymphocytes and synovial fluid
fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-
7 in an in vitro model derived from human psoriatic arthritis. J Pathol
2007, 212:47-55.
14. Anandarajah AP, Schwarz EM, Totterman S, Monu J, Feng CY, Shao T, Haas-
Smith SA, Ritchlin CT: The effect of etanercept on osteoclast precursor
frequency and enhancing bone marrow oedema in patients with
psoriatic arthritis. Ann Rheum Dis 2008, 67:296-301.
15. Chiu YG, Shao T, Feng C, Mensah KA, Thullen M, Schwarz EM, Ritchlin CT:
CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in
psoriatic arthritis. Arthritis Res Ther 2010, 12:R14.
16. Kitaura H, Zhou P, Kim HJ, Novack DV, Ross FP, Teitelbaum SL: M-CSF
mediates TNF-induced inflammatory osteolysis. J Clin Invest 2005,
115:3418-3427.
17. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J,
Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G,
Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM: Activated
T cells regulate bone loss and joint destruction in adjuvant arthritis
through osteoprotegerin ligand. Nature 1999, 402:304-309.
18. Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast-Akrad M, Lang S, Turk B,
Pietschmann P, Woloszczuk W, Haralambous S, Kollias G, Steiner G,
Smolen JS, Schett G: Tumor necrosis factor alpha-mediated joint
destruction is inhibited by targeting osteoclasts with osteoprotegerin.
Arthritis Rheum 2002, 46:785-792.
19. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, van der
Heijde D, Zhou L, Tsuji W, Newmark R: Denosumab treatment effects on
structural damage, bone mineral density, and bone turnover in
rheumatoid arthritis: a twelve-month, multicenter, randomized, double-
blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008,
58:1299-1309.
20. Fredriksson T, Pettersson U: Severe psoriasis: oral therapy with a new
retinoid. Dermatologica 1978, 157:238-244.
21. Williamson L, Dalbeth N, Dockerty JL, Gee BC, Weatherall R, Wordsworth BP:
Extended report: nail disease in psoriatic arthritis: clinically important,
potentially treatable and often overlooked. Rheumatology (Oxford) 2004,
43:790-794.
22. van der Heijde D, Kavanaugh A, Gladman DD, Antoni C, Krueger GG,
Guzzo C, Zhou B, Dooley LT, de Vlam K, Geusens P, Birbara C, Halter D,
Beutler A: Infliximab inhibits progression of radiographic damage in
patients with active psoriatic arthritis through one year of treatment:
results from the induction and maintenance psoriatic arthritis clinical
trial 2. Arthritis Rheum 2007, 56:2698-2707.
23. Dalbeth N, Smith T, Nicolson B, Clark B, Callon K, Naot D, Haskard DO,
McQueen FM, Reid IR, Cornish J: Enhanced osteoclastogenesis in patients
with tophaceous gout: urate crystals promote osteoclast development
through interactions with stromal cells. Arthritis Rheum 2008,
58:1854-1865.
24. Massey HM, Flanagan AM: Human osteoclasts derive from CD14-positive
monocytes. Br J Haematol 1999, 106:167-170.
25. Shalhoub V, Elliott G, Chiu L, Manoukian R, Kelley M, Hawkins N, Davy E,
Shimamoto G, Beck J, Kaufman SA, Van G, Scully S, Qi M, Grisanti M,
Dunstan C, Boyle WJ, Lacey DL: Characterization of osteoclast precursors
in human blood. Br J Haematol 2000, 111:501-512.
26. Williamson L, Dockerty JL, Dalbeth N, McNally E, Ostlere S, Wordsworth BP:
Clinical assessment of sacroiliitis and HLA-B27 are poor predictors of
sacroiliitis diagnosed by magnetic resonance imaging in psoriatic
arthritis. Rheumatology (Oxford) 2004, 43:85-88.
27. Docherty P, Mitchell MJ, MacMillan L, Mosher D, Barnes DC, Hanly JG:
Magnetic resonance imaging in the detection of sacroiliitis. J Rheumatol
1992, 19:393-401.
28. Daoussis D, Liossis SN, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M,
Yiannopoulos G, Andonopoulos AP: Evidence that Dkk-1 is dysfunctional
in ankylosing spondylitis. Arthritis Rheum 2010, 62:150-158.
29. Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H,
Sudo T, Shultz LD: The murine mutation osteopetrosis is in the coding
region of the macrophage colony stimulating factor gene. Nature 1990,
345:442-444.
30. Faccio R, Takeshita S, Zallone A, Ross FP, Teitelbaum SL: c-Fms and the
alphavbeta3 integrin collaborate during osteoclast differentiation. J Clin
Invest 2003, 111:749-758.
31. Maksymowych WP, Landewe R, Tak PP, Ritchlin CJ, Ostergaard M, Mease PJ,
El-Gabalawy H, Garnero P, Gladman DD, Fitzgerald O, Aletaha D, Bykerk VP,
Bathon JM, Syversen SW, Boers M, Geusens P, Inman RD, Kraus VB, Kvien TK,
Taylor WJ, Wells GA, van der Heijde D: Reappraisal of OMERACT 8 draft
validation criteria for a soluble biomarker reflecting structural damage
endpoints in rheumatoid arthritis, psoriatic arthritis, and
Dalbeth et al. Arthritis Research & Therapy 2010, 12:R164
http://arthritis-research.com/content/12/4/R164
Page 8 of 9spondyloarthritis: the OMERACT 9 v2 criteria. J Rheumatol 2009,
36:1785-1791.
32. Maksymowych WP, Fitzgerald O, Wells GA, Gladman DD, Landewe R,
Ostergaard M, Taylor WJ, Christensen R, Tak PP, Boers M, Syversen SW,
Bathon JM, Ritchlin CJ, Mease PJ, Bykerk VP, Garnero P, Geusens P, El-
Gabalawy H, Aletaha D, Inman RD, Kraus VB, Kvien TK, van der Heijde D:
Proposal for levels of evidence schema for validation of a soluble
biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic
arthritis, and ankylosing spondylitis, and recommendations for study
design. J Rheumatol 2009, 36:1792-1799.
doi:10.1186/ar3123
Cite this article as: Dalbeth et al.: Circulating mediators of bone
remodeling in psoriatic arthritis: implications for disordered
osteoclastogenesis and bone erosion. Arthritis Research & Therapy 2010
12:R164.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Dalbeth et al. Arthritis Research & Therapy 2010, 12:R164
http://arthritis-research.com/content/12/4/R164
Page 9 of 9